KR19990044460A - 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도 - Google Patents
아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도 Download PDFInfo
- Publication number
- KR19990044460A KR19990044460A KR1019980701708A KR19980701708A KR19990044460A KR 19990044460 A KR19990044460 A KR 19990044460A KR 1019980701708 A KR1019980701708 A KR 1019980701708A KR 19980701708 A KR19980701708 A KR 19980701708A KR 19990044460 A KR19990044460 A KR 19990044460A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- amount
- apo
- apolipoprotein
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000007592 Apolipoproteins Human genes 0.000 title claims 2
- 108010071619 Apolipoproteins Proteins 0.000 title claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract description 14
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 7
- -1 diazepine compound Chemical class 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 230000006806 disease prevention Effects 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- SIRFTOWPWPCSOP-UHFFFAOYSA-N 13-methyl-7-phenyl-3-thia-1,8,11,12-tetraazatricyclo trideca-2(6),4,7,10,12-pentaene Chemical compound C1=2C=CSC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 SIRFTOWPWPCSOP-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 17
- 239000007903 gelatin capsule Substances 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95114163.9 | 1995-09-09 | ||
| EP95114163 | 1995-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR19990044460A true KR19990044460A (ko) | 1999-06-25 |
Family
ID=8219597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980701708A Ceased KR19990044460A (ko) | 1995-09-09 | 1996-08-30 | 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5854238A (https=) |
| EP (1) | EP0853480B1 (https=) |
| JP (1) | JPH11512107A (https=) |
| KR (1) | KR19990044460A (https=) |
| CN (1) | CN1101680C (https=) |
| AT (1) | ATE230600T1 (https=) |
| AU (1) | AU725249B2 (https=) |
| BR (1) | BR9610390A (https=) |
| CA (1) | CA2230477A1 (https=) |
| DE (1) | DE69625696T2 (https=) |
| DK (1) | DK0853480T3 (https=) |
| ES (1) | ES2188783T3 (https=) |
| TR (1) | TR199800406T1 (https=) |
| WO (1) | WO1997009048A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6518412B1 (en) * | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6253569B1 (en) * | 1999-05-07 | 2001-07-03 | James J. Hall | Portable storage unit for game animals |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| US20040235877A1 (en) | 2001-09-14 | 2004-11-25 | Natsuki Ishizuka | Novel use of tricyclic compound |
| US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
| US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| WO2006063132A2 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| US8569288B2 (en) | 2008-10-30 | 2013-10-29 | Circomed Llc | Thienotriazolodiazepine derivatives active on apo A |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| WO2011143651A1 (en) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| AU2014292888B2 (en) | 2013-07-25 | 2018-03-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| SG11201607108XA (en) | 2014-02-28 | 2016-09-29 | Tensha Therapeutics Inc | Treatment of conditions associated with hyperinsulinaemia |
| MX383117B (es) | 2014-07-31 | 2025-03-13 | Anji Pharmaceuticals Inc | Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma. |
| KR20170032474A (ko) | 2014-08-08 | 2017-03-22 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| BR112017008714A2 (pt) | 2014-10-27 | 2017-12-19 | Tensha Therapeutics Inc | inibidores de bromodomínio |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| HK1256417A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| MX2020013608A (es) | 2018-06-13 | 2021-03-09 | Worg Pharmaceuticals Hangzhou Co Ltd | Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12303A (en) * | 1973-02-08 | 1979-01-16 | Hoffmann La Roche | Thienotriazolodiazepine derivatives |
| US4155913A (en) * | 1973-02-08 | 1979-05-22 | Hoffmann-La Roche Inc. | Thienotriazolodiazepine derivatives |
| JPS50100096A (https=) * | 1974-01-08 | 1975-08-08 |
-
1996
- 1996-08-30 DK DK96930137T patent/DK0853480T3/da active
- 1996-08-30 ES ES96930137T patent/ES2188783T3/es not_active Expired - Lifetime
- 1996-08-30 DE DE69625696T patent/DE69625696T2/de not_active Expired - Fee Related
- 1996-08-30 JP JP9510839A patent/JPH11512107A/ja not_active Ceased
- 1996-08-30 US US09/011,819 patent/US5854238A/en not_active Expired - Fee Related
- 1996-08-30 BR BR9610390A patent/BR9610390A/pt not_active Application Discontinuation
- 1996-08-30 CA CA002230477A patent/CA2230477A1/en not_active Abandoned
- 1996-08-30 TR TR1998/00406T patent/TR199800406T1/xx unknown
- 1996-08-30 EP EP96930137A patent/EP0853480B1/en not_active Expired - Lifetime
- 1996-08-30 AT AT96930137T patent/ATE230600T1/de not_active IP Right Cessation
- 1996-08-30 CN CN96196835A patent/CN1101680C/zh not_active Expired - Fee Related
- 1996-08-30 KR KR1019980701708A patent/KR19990044460A/ko not_active Ceased
- 1996-08-30 WO PCT/EP1996/003814 patent/WO1997009048A1/en not_active Ceased
- 1996-08-30 AU AU69303/96A patent/AU725249B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK0853480T3 (da) | 2003-05-05 |
| EP0853480A1 (en) | 1998-07-22 |
| DE69625696T2 (de) | 2003-10-16 |
| AU6930396A (en) | 1997-03-27 |
| EP0853480B1 (en) | 2003-01-08 |
| US5854238A (en) | 1998-12-29 |
| TR199800406T1 (en) | 1998-05-21 |
| CN1195989A (zh) | 1998-10-14 |
| CN1101680C (zh) | 2003-02-19 |
| AU725249B2 (en) | 2000-10-12 |
| MX9801753A (es) | 1998-08-30 |
| BR9610390A (pt) | 1999-07-06 |
| ATE230600T1 (de) | 2003-01-15 |
| JPH11512107A (ja) | 1999-10-19 |
| ES2188783T3 (es) | 2003-07-01 |
| WO1997009048A1 (en) | 1997-03-13 |
| DE69625696D1 (de) | 2003-02-13 |
| CA2230477A1 (en) | 1997-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR19990044460A (ko) | 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도 | |
| US6136859A (en) | Pharmaceutical formulation for treating liver disorders | |
| US20020173510A1 (en) | Formulation for menopausal women | |
| US6852870B2 (en) | Omega-3 fatty acids in the treatment of depression | |
| WO1997039759A2 (en) | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder | |
| EP1269860B1 (en) | Pharmaceutical composition | |
| US6358937B1 (en) | Method for the treatment of cancer using phosphatidic acid-comprising compositions | |
| EP0629400A1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| EP1093817B1 (en) | Composition containing compounds with adrenergic activity and vegetable extracts of crataegus and gingko biloba for the treatment of overweight and obesity | |
| WO2000043017A1 (en) | Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human | |
| US6344482B1 (en) | Omega-3 fatty acids in the treatment of bipolar disorder | |
| JP2001518484A (ja) | アルコール中毒者の禁断症状とアルコールに対する渇望を抑制するための、および、健康な人のアルコールの濫用を防ぐための組成物 | |
| DE3739700A1 (de) | Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin | |
| JPS6299323A (ja) | 高脂血症剤 | |
| DE60020833T2 (de) | Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag | |
| US5627152A (en) | Method for increasing bodyweight | |
| JP2002527472A (ja) | 消化不良の処置 | |
| MXPA98001753A (en) | Use of a thenotriazolodiazepine to increase apolipoprotein levels | |
| WO2003009840A1 (en) | Composition comprising at least one lipase inhibitor and carnitine | |
| US20040225010A1 (en) | Method for decreasing cholesterol level in blood | |
| JPH0436136B2 (https=) | ||
| CN120187454A (zh) | β-肾上腺素能激动剂和毒蕈碱性拮抗剂组合物及使用方法 | |
| HK40036800A (en) | Methods for increasing brain functionality using 2-fucosyl-lactose | |
| HK1051784B (en) | Pharmaceutical composition | |
| HK1051784A1 (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19980306 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20010829 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20030929 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20031230 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20030929 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |